TweenVax for Cancer Prevention
What You Need to Know Before You Apply
What is the purpose of this trial?
This trial aims to boost HPV vaccination rates in adolescents by testing a new program, TweenVax, against standard promotion methods. The focus is on preventing HPV-related cancers by encouraging early vaccination, ideally by age 13. TweenVax provides education and tools for healthcare providers, parents, and young patients to improve vaccination messaging. The trial seeks children aged 9-12 who haven't started the HPV vaccine and are visiting a participating doctor's office. As an unphased trial, this study offers a unique opportunity to contribute to important research that could enhance public health strategies for HPV prevention.
Will I have to stop taking my current medications?
The trial information does not specify whether participants need to stop taking their current medications.
What prior data suggests that the TweenVax intervention is safe for improving HPV vaccination rates in adolescents?
Research has shown that HPV (human papillomavirus) vaccines are very safe. For over 15 years, studies have confirmed that these vaccines effectively prevent diseases caused by HPV. They offer long-lasting protection with a very low risk of serious side effects. Most side effects are mild, such as soreness at the injection site or a slight fever.
The TweenVax program supports the use of these safe vaccines but is not a vaccine itself. It aims to increase HPV vaccination rates by providing better education and recommendations. As a promotional tool rather than a medical treatment, TweenVax poses no safety concerns. Instead, it helps more people access and benefit from the safe and effective HPV vaccines available.12345Why are researchers excited about this trial?
Researchers are excited about TweenVax for cancer prevention because it integrates multiple levels of intervention, including practice, provider, parent, and patient engagement. Unlike the standard adolescent vaccination practices, TweenVax offers a comprehensive approach by involving parents and adolescents directly through an interactive application. This app delivers personalized vaccination information during clinical visits, aiming to enhance understanding and participation. By combining technology and education at multiple levels, TweenVax has the potential to improve vaccination rates and ultimately aid in cancer prevention more effectively than current standard practices.
What evidence suggests that this trial's interventions could be effective for improving HPV vaccination rates?
Research shows that increasing HPV vaccination rates can prevent many HPV-related cancers. Studies have found that widespread use of the HPV vaccine can greatly reduce cervical cancer cases. In this trial, the TweenVax program aims to increase HPV vaccine use by educating doctors, parents, and patients. Participants in Arm I will receive all TweenVax components and training at practice, provider, parent, and patient levels. This comprehensive approach is expected to be more effective than current methods in increasing vaccination rates among young people.16789
Who Is on the Research Team?
Robert Bednarczyk, PhD
Principal Investigator
Emory University Hospital/Winship Cancer Institute
Are You a Good Fit for This Trial?
The TweenVax trial is for adolescents who need the HPV vaccine, which can prevent certain types of cancer. The study aims to see if a special educational program (TweenVax) helps increase vaccination rates compared to usual ways of promoting vaccines.Inclusion Criteria
Timeline for a Trial Participant
Screening
Participants are screened for eligibility to participate in the trial
Intervention
Practices receive TweenVax components and trainings related to practice, provider, staff, parent, and adolescent-level intervention
Follow-up
Participants are monitored for initiation and completion of HPV vaccine by 13 years of age
What Are the Treatments Tested in This Trial?
Interventions
- TweenVax
Trial Overview
This trial tests an intervention called TweenVax that includes education at different levels: practice, provider, parent, and patient. It's designed to teach best practices for vaccination promotion and provide clear information about the HPV vaccine.
How Is the Trial Designed?
3
Treatment groups
Experimental Treatment
Active Control
Practices receive components and trainings related to the practice and provider-level intervention on study.
Practices receive all TweenVax components and trainings related to the practice, provider and staff, parent and adolescent-level intervention. Parents receive access to the TweenVax application and receive TweenVax vaccination information using the provided tablet during clinical encounters on study.
Practices continue to offer standard of care adolescent vaccination promotion practices to adolescent patients on study.
Find a Clinic Near You
Who Is Running the Clinical Trial?
Emory University
Lead Sponsor
National Cancer Institute (NCI)
Collaborator
Citations
Project Details - NIH RePORTER
Our research team has developed and pilot-tested an intervention package – TweenVax – designed to improve HPV vaccine uptake at the practice-, provider-, and ...
A Vaccine Promotion Package (TweenVax) to Improve ...
This clinical trial compares the effect of a vaccine promotional intervention, TweenVax, to standard of care vaccination promotion practices on ...
TweenVax for Cancer Prevention
This N/A medical study run by Emory University is evaluating whether TweenVax will have tolerable side effects & efficacy for patients with Carcinoma.
https://dph.georgia.gov/document/document/evaluati...
Recent data show that 16.8 percent of cancer survivors report being current smokers and almost 31 percent report no leisure time physical activity (Georgia ...
5.
cancer.gov
cancer.gov/news-events/cancer-currents-blog/2020/hpv-vaccine-prevents-cervical-cancer-sweden-studyStudy Confirms HPV Vaccine Prevents Cervical Cancer - NCI
Widespread HPV vaccine use dramatically reduces the number of women who will develop cervical cancer, a large study has shown.
HPV Vaccine Safety and Effectiveness Data
More than 15 years of monitoring and research have accumulated reassuring evidence that HPV vaccination provides safe, effective, and long-lasting protection.
Real-world safety of HPV vaccines over 18 y - PubMed Central
Although clinical trials have established favorable safety profiles, long-term, brand-specific real-world data remain limited. We evaluated ...
HPV Vaccine Safety and Effectiveness
HPV vaccination could prevent more than 90% of these cancers from ever developing. The vaccine is made from one protein from the virus and is ...
Testing RG1-VLP Vaccine to Prevent HPV-related Cancers
This phase I trial tests the safety, side effects, and best dose of RG1-virus-like particle (VLP) in preventing human papillomavirus ...
Unbiased Results
We believe in providing patients with all the options.
Your Data Stays Your Data
We only share your information with the clinical trials you're trying to access.
Verified Trials Only
All of our trials are run by licensed doctors, researchers, and healthcare companies.